NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $108.07 -0.06 (-0.06%) (As of 07/8/2024 ET) Add Compare Share Share Today's Range$107.87▼$108.7950-Day Range$97.13▼$108.1352-Week Range$92.19▼$108.79Volume1.43 million shsAverage Volume1.17 million shsMarket Capitalization$220.90 billionP/E Ratio14.58Dividend Yield2.25%Price Target$118.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Novartis alerts: Email Address Novartis MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside9.3% Upside$118.13 Price TargetShort InterestBearish0.32% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.74Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth12.50%From $7.28 to $8.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector683rd out of 876 stocksPharmaceutical Preparations Industry321st out of 416 stocks 1.1 Analyst's Opinion Consensus RatingNovartis has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageNovartis has only been the subject of 4 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.32% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Novartis has recently increased by 60.20%, indicating that investor sentiment is decreasing significantly. Previous Next 2.5 Dividend Strength Dividend YieldNovartis pays a meaningful dividend of 2.25%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 32.79%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.67% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVS. Previous Next 2.6 News and Social Media Coverage News SentimentNovartis has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Novartis this week, compared to 10 articles on an average week.Search Interest10 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows14 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Novartis are expected to grow by 12.50% in the coming year, from $7.28 to $8.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 14.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 14.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.03.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.66. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.This Crypto bull market is not even halfway over About Novartis Stock (NYSE:NVS)Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More NVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVS Stock News HeadlinesJuly 4, 2024 | americanbankingnews.comNovartis (NYSE:NVS) PT Raised to $122.50June 17, 2024 | investorplace.com7 Breakthrough Biotech Stocks for a Shot of Portfolio AdrenalineJuly 9, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… June 13, 2024 | globenewswire.comNovartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy TreatmentJune 6, 2024 | reuters.comNovartis and others face Italy antitrust probe over eye drugJune 4, 2024 | investorplace.comThe 3 Most Undervalued Healthcare Stocks to Buy in June 2024June 3, 2024 | seekingalpha.comNovartis AG (NVS) Investor Event at ASCO Conference Call (Transcript)May 31, 2024 | reuters.comNovartis leukemia drug more effective than older treatments in trialJuly 9, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 31, 2024 | globenewswire.comNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CMLMay 30, 2024 | globenewswire.comNovartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticariaMay 28, 2024 | msn.comTravere gains on Novartis data for Filspari rival, Calliditas buyoutMay 28, 2024 | theglobeandmail.comNOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIPMay 28, 2024 | finance.yahoo.comNovartis and Clarius partner for psoriatic arthritis care in CanadaMay 28, 2024 | msn.comNovartis reports Phase 3 results for IgA nephropathy treatmentMay 27, 2024 | finance.yahoo.comNovartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trialMay 27, 2024 | seekingalpha.comNovartis: Buy This Blue-Chip Dividend Stock On Sale NowMay 25, 2024 | globenewswire.comNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioSee More Headlines Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/23/2024Today7/08/2024Next Earnings (Confirmed)7/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$118.13 High Stock Price Target$122.50 Low Stock Price Target$114.00 Potential Upside/Downside+9.3%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$7.41 Trailing P/E Ratio14.58 Forward P/E Ratio14.84 P/E Growth1.66Net Income$14.85 billion Net Margins31.33% Pretax Margin20.00% Return on Equity32.15% Return on Assets13.59% Debt Debt-to-Equity Ratio0.43 Current Ratio0.90 Quick Ratio0.71 Sales & Book Value Annual Sales$45.44 billion Price / Sales4.86 Cash Flow$11.11 per share Price / Cash Flow9.73 Book Value$22.87 per share Price / Book4.73Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$220.90 billion OptionableOptionable Beta0.57 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Vasant Narasimhan M.D. (Age 48)Chief Executive Officer Comp: $8.01MMr. Harry Kirsch (Age 59)Chief Financial Officer Comp: $3.99MMr. Victor Bulto (Age 46)President of US Comp: $3.28MDr. Patrick Horber M.D. (Age 54)President of International Comp: $7.31MDr. Steffen Lang Ph.D. (Age 57)President of Operations Comp: $2.34MPaul PenepentHead of Group Financial Reporting and AccountingMs. Sloan SimpsonGlobal Head of Investor RelationsDr. Klaus Moosmayer Ph.D. (Age 56)Chief Ethics, Risk & Compliance Officer Comp: $1.55MMs. Karen L. Hale (Age 56)Chief Legal Officer Comp: $2.34MDr. Robert Kowalski Pharm.D. (Age 56)Chief People & Organization Officer Comp: $2.1MMore ExecutivesKey CompetitorsEli Lilly and CompanyNYSE:LLYNovo Nordisk A/SNYSE:NVOJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVView All CompetitorsInstitutional OwnershipDouglas Lane & Associates LLCSold 2,662 shares on 7/8/2024Ownership: 0.009%Boston Common Asset Management LLCSold 100 shares on 7/8/2024Ownership: 0.008%Beach Investment Counsel Inc. PASold 3,813 shares on 7/8/2024Ownership: 0.002%Woodstock CorpSold 150 shares on 7/8/2024Ownership: 0.000%Thurston Springer Miller Herd & Titak Inc.Bought 587 shares on 7/5/2024Ownership: 0.000%View All Institutional Transactions Should I Buy Novartis Stock? NVS Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Novartis AG: Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally, focusing on therapeutic areas such as cardiovascular, renal, metabolic, and immunology. Novartis AG offers prescription medicines for patients and physicians, providing a wide range of healthcare solutions. Cons Investors should be bearish about investing in Novartis AG for these reasons: Novus Energy, Inc. (Novus) is a junior oil and gas company, not related to Novartis AG, which may cause confusion or misinformation for investors. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com. NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the beginning of the year. Since then, NVS stock has increased by 7.0% and is now trading at $108.07. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) posted its quarterly earnings results on Tuesday, April, 23rd. The company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.73 by $0.07. The business had revenue of $11.83 billion for the quarter, compared to analysts' expectations of $11.50 billion. Novartis had a net margin of 31.33% and a trailing twelve-month return on equity of 32.15%. What is Vas Narasimhan's approval rating as Novartis' CEO? 938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Novartis have any subsidiaries? The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others. Who are Novartis' major shareholders? Novartis' top institutional shareholders include Douglas Lane & Associates LLC (0.01%), Boston Common Asset Management LLC (0.01%), Beach Investment Counsel Inc. PA and First Hawaiian Bank. How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD). This page (NYSE:NVS) was last updated on 7/9/2024 by MarketBeat.com Staff From Our PartnersBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredYoung billionaire opens the door for millions of AmericansYou can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. house...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
